APA (7th ed.) Citation

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2012). Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Research, 72(24a), 2171. https://doi.org/10.1158/0008-5472.SABCS12-S1-6

Chicago Style (17th ed.) Citation

Finn, R. S., et al. "Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole Vs Letrozole Alone for First-line Treatment of ER+/HER2- Advanced Breast Cancer (BC)." Cancer Research 72, no. 24a (2012): 2171. https://doi.org/10.1158/0008-5472.SABCS12-S1-6.

MLA (9th ed.) Citation

Finn, R. S., et al. "Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole Vs Letrozole Alone for First-line Treatment of ER+/HER2- Advanced Breast Cancer (BC)." Cancer Research, vol. 72, no. 24a, 2012, p. 2171, https://doi.org/10.1158/0008-5472.SABCS12-S1-6.